New hope for patients whose lymphoma Won't quit

NCT ID NCT05529069

Summary

This study is testing whether a combination of two oral drugs, pirtobrutinib and venetoclax, can help control mantle cell lymphoma that has come back or stopped responding to other therapies. It will enroll about 30 adults whose cancer has relapsed or is refractory, including those who have already tried other common treatments. The main goal is to see how well the combination works and how safe it is for these patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.